首页> 美国卫生研究院文献>Thrombosis Journal >Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar
【2h】

Rates of clinically apparent heparin-induced thrombocytopenia for unfractionated heparin vs. low molecular weight heparin in non-surgical patients are low and similar

机译:非手术患者肝素对低分子量肝素与低分子量肝素的临床上明显的肝素诱导的血小板减少的发生率低且相似

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

With the growing use of low-molecular-weight heparins (LMWH) for the treatment and prevention of venous thromboembolism (VTE), it is important to provide an evidence-based comparison with unfractionated heparin (UFH) concerning rates of heparin-induced thrombocytopenia (HIT). Such comparisons are essential in clinical decision-making and cost-modeling. In this paper we review data regarding non-surgical (medical) patients. We conclude that the lack of uniform evaluation and standardized testing for HIT in the current literature precludes making a reliable estimate of the relative risk of HIT in UFH vs. LMWH in either the treatment or prevention of VTE in non-surgical patients. However, current data suggest that the risk of thrombocytopenia and HIT is low and similar for non-surgical patients who receive either LMWH or UFH.
机译:随着低分子量肝素(LMWH)在治疗和预防静脉血栓栓塞(VTE)中的使用的日益增长,重要的是就肝素诱导的血小板减少症的发生率与普通肝素(UFH)提供基于证据的比较(击中)。这种比较对于临床决策和成本建模至关重要。在本文中,我们回顾了有关非手术(医学)患者的数据。我们得出的结论是,当前文献中缺乏针对HIT的统一评估和标准化测试,因此无法对非手术患者VTE的治疗或预防中UFH与LMWH的HIT相对风险进行可靠的估计。然而,目前的数据表明,接受LMWH或UFH的非手术患者的血小板减少和HIT风险较低,且相似。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号